Eating red meat, processed meat, and a high fat-diet after a prostate cancer diagnosis may affect a man’s risk of death from the disease. After a prostate cancer diagnosis, men who ate foods rich...
Researchers identified mutations in leukemias, including acute lymphoblastic leukemia that may make them amenable to FDA-approved ALK inhibitors.
A decreased number of hours spent eating each day and an increased number of hours spent fasting overnight might reduce a woman's risk for breast cancer.
An investigational therapeutic targets egions of the epidermal growth factor receptor in patients whose colorectal cancers became resistant.
Study finds an association between the use of cholesterol-lowering statins and the risk of death lung cancer death among patients with the disease.
Men with metastatic, castrate-resistant prostate cancer with mutations in genes linked to DNA repair responded to an investigational targeted therapeutic.
A small, early-phase trial of an investigational cancer immunotherapy yielded "durable responses" for patients with advanced melanoma and ocular melanoma.
Trial data first presented at the AACR Annual Meeting 2014, showed drug doubled progression-free survival for a certain type of metastatic breast cancer.
Research is beginning to reveal that the metabolic health problems often associated with being or obese can themselves influence risk for certain cancers.
The FDA's approval of a targeted therapeutic called lenvatinib provides another option for patients certain forms of thyroid cancer.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More